全球结核病诊断市场规模、份额、趋势和成长分析报告（2026-2034年）

预计结核病诊断市场将从 2025 年的 294 万美元成长到 2034 年的 497 万美元，2026 年至 2034 年的复合年增长率为 6.03%。

随着医疗系统将感染疾病的早期发现和有效控制列为优先事项，结核病诊断市场正在迅速发展。传统的诊断方法，例如痰液涂片显微镜检查，正逐渐被先进的分子检测、γ-干扰素释放试验和快速照护现场所补充和取代。人们对多重抗药性结核病的日益关注，正在加速高灵敏度和高特异性诊断工具的应用。

未来的发展预计将专注于自动化、小型化和数位化连接。次世代定序技术和人工智慧增强的诊断演算法可望提高准确性、缩短检测时间，并为临床医生提供实用资讯。尤其是在资源匮乏的环境中，携带式诊断平台的普及使得分散式检查成为可能，并使患者能够快速获得医疗保健服务。诊断技术与行动医疗平台的整合正在建构能够全面管理监测、监控和治疗依从性的系统。

全球卫生倡议、政府计画以及旨在根除结核病的公私合营进一步增强了市场前景。新型生物标记和先进成像技术的研发投入不断增加，预计将进一步巩固诊断生态系统。随着创新加速和全球意识的不断提高，结核病诊断市场有望在减轻全球疾病负担方面发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球结核病诊断市场：按类型划分

• 市场分析、洞察与预测
• 潜伏感染的检测（皮肤试验和γ-干扰素释放试验）
• 噬菌体检测
• 抗菌药物抗药性检测（DST）
• 核酸检测
• X射线影像
• 细胞激素检测分析
• 其他的

第五章：全球结核病诊断市场：依最终用途划分

• 市场分析、洞察与预测
• 诊断检查室
• 医院和诊所
• 其他的

第六章 全球结核病诊断市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Abbott
  • Qiagen
  • Thermo Fisher Scientific Inc
  • BD
  • F. Hoffmann-La Roche AG
  • Hologic Inc
  • Cepheid
  • DiaSorin SPA
  • Hain Lifescience GmbH
  • Oxford Immunotec

The Tuberculosis Diagnostics Market size is expected to reach USD 4.97 Million in 2034 from USD 2.94 Million (2025) growing at a CAGR of 6.03% during 2026-2034.

The tuberculosis diagnostics market is evolving rapidly as healthcare systems prioritize early detection and effective management of this infectious disease. Traditional diagnostic methods, such as sputum microscopy, are being supplemented and replaced by advanced molecular tests, interferon-gamma release assays, and rapid point-of-care solutions. Growing concerns over multidrug-resistant tuberculosis are accelerating adoption of highly sensitive and specific diagnostic tools.

Future developments will emphasize automation, miniaturization, and digital connectivity. Next-generation sequencing and AI-enhanced diagnostic algorithms are expected to improve accuracy, reduce turnaround times, and provide actionable insights for clinicians. Portable diagnostic platforms are gaining traction, particularly in low-resource settings, enabling decentralized testing and faster patient access to care. Integration of diagnostics with mobile health platforms is creating comprehensive systems for monitoring, surveillance, and treatment adherence.

The market outlook is reinforced by international health initiatives, government programs, and public-private partnerships aimed at eradicating tuberculosis. Rising investments in R&D for novel biomarkers and advanced imaging technologies are expected to further strengthen the diagnostic ecosystem. As innovation accelerates and global awareness increases, the tuberculosis diagnostics market is positioned to play a crucial role in reducing disease burden worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Detection of Latent Infection (Skin Test & IGRA)
• Phage Assay
• Detection of Drug Resistance (DST)
• Nucleic Acid Testing
• Radiographic Method
• Cytokine Detection Assay
• Others

By End-use

• Diagnostic Laboratories
• Hospitals & Clinics
• Others

COMPANIES PROFILED

• Abbott, Qiagen, Thermo Fisher Scientific Inc, BD, F HoffmannLa Roche AG, Hologic Inc, Cepheid, DiaSorin SpA, Hain Lifescience GmbH, Oxford Immunotec
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Detection of Latent Infection (Skin Test & IGRA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Phage Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Detection of Drug Resistance (DST) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Nucleic Acid Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Radiographic Method Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Cytokine Detection Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL TUBERCULOSIS DIAGNOSTICS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Abbott
  • 8.2.2 Qiagen
  • 8.2.3 Thermo Fisher Scientific Inc
  • 8.2.4 BD
  • 8.2.5 F. Hoffmann-La Roche AG
  • 8.2.6 Hologic Inc
  • 8.2.7 Cepheid
  • 8.2.8 DiaSorin S.P.A
  • 8.2.9 Hain Lifescience GmbH
  • 8.2.10 Oxford Immunotec